Rosacea is a chronic inflammatory skin disorder affecting predominantly adult patients. The aim of the current investigation was to evaluate clinical response by using quality of life assessment before and after an IPL (intensive pulsed light) therapy course for patients sufferring from rosacea treated in the outpatient clinic “Health and Aesthetics” in Rīga during a one-year period (in 2016). All patients presented with typical clinical symptoms of rosacea on the face — acneiform papules, pustules, telangiectasia, centrofacial erythema, and complaints about flushing and burning. In the current study, 100 rosacea patients treated with IPL therapy were selected. Each patient filled in the quality of life questionnaire before and after two courses of IPL therapy. The interval between IPL therapy sessions was one month. The results reflected comprehensive benefit from IPL therapy for all rosacea patients. No serious side effects from IPL therapy were detected. Side effects like mild eythema after procedure (75%), mild oedema (10%), vesiculation (3%), and hyperpigmentation (8%) were completely resolved within four weeks after completion of treatment. In all patients, quality of life assessment showed a statistically significant increase after two courses of IPL therapy.
Histamine has an important role in the process of the gastric mucosa inflammation acting via histamine receptor H2 (encoded by the gene HRH2). Single nucleotide polymorphism of the enhancer element of HRH2 gene promoter rs2067474 (1018G>A)may be associated with changes of expression of the receptor. We attempted to clarify the association of this polymorphism with gastric cancer and/or atrophic gastritis in the Latvian (Caucasian) population. The study group consisted of 121 gastric cancer patients and 650 patients with no evidence of gastric neoplasia on upper gastrointestinal endoscopy. Genotyping for rs2067474 was performed with the TaqMan probe-based system using a commercially available probe for RT-PCR. The frequency of the A allele in the gastric cancer group was 0.41% and in the control group — 1.54% (p = 0.231). No significant differences were found comparing genotypes between gastric cancer versus control patients (OR = 0.236, CI95% = 0.030–1.896), patients with (n = 165) versus without (n = 485) gastric metaplastic lesions (OR = 0.854, CI95% = 0.288–2.540) and patients with (n = 297) and without (n = 353) gastric atrophic lesions (OR = 1.145, CI95% = 0.451–2.906). Our findings suggest that the HRH2 -1018G>A polymorphism (rs2067474) is neither associated with gastric cancer nor the grade of atrophic gastritis in the Latvian (Caucasian) population.